196 related articles for article (PubMed ID: 32232973)
1. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C
ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973
[TBL] [Abstract][Full Text] [Related]
2. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
[TBL] [Abstract][Full Text] [Related]
4. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T
J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1.
Li Z; Zhang Z; Sun H; Xu L; Jiang C
Bioorg Chem; 2019 Oct; 91():103148. PubMed ID: 31376784
[TBL] [Abstract][Full Text] [Related]
6. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
7. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
[TBL] [Abstract][Full Text] [Related]
9. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
12. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
[TBL] [Abstract][Full Text] [Related]
13. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
15. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
Zhao XZ; Tsuji K; Hymel D; Burke TR
Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B
Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699
[TBL] [Abstract][Full Text] [Related]
17. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
18. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
Reindl W; Gräber M; Strebhardt K; Berg T
Anal Biochem; 2009 Dec; 395(2):189-94. PubMed ID: 19716361
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C
Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276
[TBL] [Abstract][Full Text] [Related]
20. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
